In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

"Heart failure: across-sectional study about quality of life, anxiety depresion and detection of possible health and cardiovascular problems"

Session Poster Session 2

Speaker Rafael Mesa Rico

Event : EuroHeartCare 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Treatment
  • Session type : Poster Session

Authors : E Marques-Sule (Valencia,ES), M Romero Fuentes (Valencia,ES), S Senra (Basingstoke,GB), L Almenar (Valencia,ES), R Lopez Vilella (Valencia,ES), S Perez-Alenda (Valencia,ES), F Querol-Fuentes (Valencia,ES), R Mesa Rico (Marbella,ES), AL Fernadez Oliver (Malaga,ES)

E Marques-Sule1 , M Romero Fuentes1 , S Senra2 , L Almenar3 , R Lopez Vilella3 , S Perez-Alenda3 , F Querol-Fuentes1 , R Mesa Rico4 , AL Fernadez Oliver5 , 1University of Valencia, Physio-therapy - Valencia - Spain , 2Basingstoke and North Hamphire Hospital, Research and Development - Basingstoke - United Kingdom of Great Britain & Northern Ireland , 3University Hospital La Fe, Heart failure and heart transplant unit - Valencia - Spain , 4Hospital Costa del Sol - Marbella - Spain , 5University Hospital Virgen de la Victoria - Malaga - Spain ,


Background: Quality of life, anxiety, depression and detection of health and cardiovascular complications are very important parameters in patients with heart failure (HF) that require the initiation of a physical activity (PA) program.

Purpose: This study aimed at measuring the quality of life, anxiety and depression levels in patients diagnosed with HF, as well as detecting other underlying general health and cardiovascular problems in order to recommend consulting a health professional prior to initiating a PA program.

Method: A cross-sectional study was performed in outpatients with a diagnostic of HF (n=110). This study complies with the Declaration of Helsinki and was approved by the Regional Ethics Committee. The quality of life was measured via Short-From 36. Anxiety and depression levels were measured with the Hospital Anxiety and Depression Scale. The detection of health and cardiovascular problems in patients willing to start a PA program were measured with the Physical Activity Readiness Questionnaire PAR-Q.

Results: The less affected domains for quality of life were physical function, general health, vitality and emotional role, while the most affected domains were physical pain, social function, mental health and physical role. It was found that 43.2% of participants had a good quality of life. Conversely, 22% of participants showed a high level of anxiety, whilst 12.2% presented a high level of depression. Finally, only 37% were allowed to perform PA without consulting a health professional, while 63% were recommended to consult a health professional prior to initiating any sort of PA.

Conclusion: The quality of life of HF patients was low and the most affected domains were physical pain, social function, mental health and physical role. Anxiety and depression levels were low, although anxiety was more present than depression. 63% of participants required professional input by a health professional prior to starting any PA.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are